AstraZeneca’s AZN third-quarter 2024 core earnings of $1.04 per American depositary share (ADS) beat the Zacks Consensus ...

Beyfortus made almost $600 million in its first full year on the market in 2023, even though it was held back by manufacturing capacity constraints, and AZ and Sanofi are predicting it will cross ...

Key Takeaways Zacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

Aug 17, 2024 18:48 Sanofi Gets CDSCO Nod for Beyfortus in India - Prevention of RSV Sanofi India receives marketing authorization for Beyfortus, a treatment for preventing Respiratory Syncytial Virus ...

A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly – the ...

Sanofi (SNY) has released an update. Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with ...

Sanofi reported total sales of €34,947 million, an increase of 0.5%. The company suffered many patent expirations and were impacted by generic competition – net sales lost came to €1,345 ...

Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year of age. Specifically, the ...

Sanofi India Limited (Previously known as Aventis Pharma Limited) was incorporated in May 1956. The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11 2012. The ...